Fulcrum Therapeutics is a rare-disease biopharmaceutical company based in Massachusetts. It lobbied Congress mainly on health issues, specifically providing education and advocacy about sickle cell disease and a 2025 bill (H.R. 1796 / S. 735) on research, surveillance, prevention, and treatment of heritable blood disorders. Its filings show modest in-house spending and use of the McManus Group as a lobbyist.
Show the dominant industry call, how mixed the client looks, and the allocation across the top labeled sectors.
Annual totals based on disclosed filing amounts.
Issue rankings are based on disclosed activity mentions, with filing amounts apportioned evenly across issues within the same filing.
The lobbying registrants handling this client, ranked by disclosed filing amounts.
Lobbyists are ranked by appearances and an equal share of each filing's reported amount.
JOHN MCMANUS
The latest disclosures for this client.
THE MCMANUS GROUP
2TTHE MCMANUS GROUP
Q1The entities named in disclosed activities are the clearest available signal for where the client is aiming attention.
THE MCMANUS GROUP
ms LAWREN D GEER
THE MCMANUS GROUP
ABIGAIL SMITH
THE MCMANUS GROUP
ms MARY GRACE DARCEY
THE MCMANUS GROUP
THE MCMANUS GROUP
Q4THE MCMANUS GROUP
Q3THE MCMANUS GROUP
Q2THE MCMANUS GROUP
Q1THE MCMANUS GROUP
RR